23 completed. 23 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 23 | Completed 23 |
| Phase 2 | 2 | Completed 2 |
Follow Nasal Polyps: new trials by email Literature Review of Nasal Polyps trials Research Report on Nasal Polyps
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps Depemokimab (GSK3511294), Placebo - Nasal Polyps | Phase 3 | Completed | GlaxoSmithKline | 276 | 2022-04-22 | 2025-12-03 |
| Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2) Depemokimab (GSK3511294), Placebo - Nasal Polyps | Phase 3 | Completed | GlaxoSmithKline | 264 | 2022-04-18 | 2025-09-09 |
| Role of Doxycycline in Chronic Rhinosinusitis With Nasal Polyps Doxycycline 100 mg Oral Tablet, Prednisolone 20 mg - Nasal Polyps, Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Completed | Assiut University | 60 | 2021-07-01 | 2024-08-13 |
| Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis Experimental: Tezepelumab, Placebo, Mometasone furoate or equivalent intranasal corticosteroid - Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Completed | AstraZeneca | 416 | 2021-04-22 | 2026-01-27 |
| Efficacy and Safety of Mepolizumab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)/ Eosinophilic Chronic Rhinosinusitis (ECRS) Mepolizumab, Placebo, Standard of care - Nasal Polyps | Phase 3 | Completed | GlaxoSmithKline | 169 | 2021-02-08 | 2026-07-22 |
| NAsal Polyps: Inflammatory & Molecular Phenotyping of Responders to Benralizumab Benralizumab, Placebo - Nasal Polyps | Phase 3 | Completed | Humanitas Clinical and Research Center | 14 | 2020-02-24 | 2024-10-31 |
| Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma Fevipiprant 150 mg, Fevipiprant 450 mg, Placebo - Nasal Polyps | Phase 3 | Completed | Novartis Pharmaceuticals | 98 | 2019-03-26 | 2021-10-11 |
| Efficacy & Safety of OPN-375 Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video Fluticasone Propionate - Nasal Polyposis | Phase 3 | Completed | Optinose US Inc. | 11 | 2018-06-07 | 2020-08-03 |
| An Extension Study of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps Omalizumab, Placebo - Nasal Polyps, Chronic Rhinosinusitis | Phase 3 | Completed | Hoffmann-La Roche | 249 | 2018-05-09 | 2022-04-04 |
| Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis Benralizumab 30 mg SC + Mometasone Furoate, Matching placebo SC + Mometasone Furoate - Nasal Polyposis | Phase 3 | Completed | AstraZeneca | 413 | 2018-01-15 | 2021-10-12 |
| A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps Omalizumab, Placebo - Nasal Polyps, Chronic Rhinosinusitis | Phase 3 | Completed | Hoffmann-La Roche | 127 | 2017-11-21 | 2020-03-23 |
| A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps Omalizumab, Placebo - Nasal Polyps, Chronic Rhinosinusitis | Phase 3 | Completed | Hoffmann-La Roche | 138 | 2017-11-15 | 2020-03-23 |
| Safety Evaluation of Repeat Placement of the S8 Sinus Implant in Chronic Sinusitis Patients With Nasal Polyps (ENCORE) S8 Sinus Implant - Chronic Sinusitis, Nasal Polyposis | Phase 3 | Completed | Intersect ENT | 50 | 2017-11-13 | 2019-11-27 |
| Effect of Mepolizumab in Severe Bilateral Nasal Polyps Mepolizumab, Placebo, Mometasone furoate - Nasal Polyps | Phase 3 | Completed | GlaxoSmithKline | 414 | 2017-05-25 | 2026-07-22 |
| A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps Dupilumab SAR231893 (REGN668), Placebo, Mometasone furoate 50 micrograms - Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) | Phase 3 | Completed | Sanofi | 276 | 2016-12-05 | 2019-07-25 |
| S8 Sinus Implant in Chronic Sinusitis Patients With Recurrent Nasal Polyps S8 Sinus Implant, Mometasone furoate nasal spray, Sham - Chronic Sinusitis, Nasal Polyposis | Phase 3 | Completed | Intersect ENT | 300 | 2014-12-01 | 2018-08-15 |
| 12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device Fluticasone Propionate - Nasal Polyps | Phase 3 | Completed | Optinose US Inc. | 223 | 2013-09-01 | 2018-01-24 |
| Steroid-Releasing S8 Sinus Implant for Recurrent Nasal Polyps S8 Sinus Implant, Sham procedure, Mometasone furoate nasal spray - Chronic Sinusitis, Nasal Polyps | Phase 2 / Phase 3 | Completed | Intersect ENT | 100 | 2013-01-01 | 2018-07-20 |
| A Study of the Effectiveness and Safety of Mometasone Furoate Nasal Spray (MFNS, SCH 032088) for the Treatment of Nasal Polyps (P05604) Mometasone Furoate Nasal Spray (MFNS), Placebo for MFNS - Nasal Polyps | Phase 3 | Completed | Organon and Co | 748 | 2011-06-01 | 2024-05-21 |
| The Effect of Preoperative Oral Prednisone on the Operative Field During Nasal Polypectomy. Oral Prednisone, Placebo comparator - Nasal Polyps | Phase 3 | Completed | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | 34 | 2010-11-01 | 2014-01-10 |
Showing 20 of 23. Sign in to see all of them.
Nose Diseases (2) · Asthma (1) · Blood Loss, Surgical (1) · Bronchial Diseases (1) · Fistula (1) · Lung Diseases (1) · Otorhinolaryngologic Diseases (1) · Polyps (1) · Respiratory Hypersensitivity (1) · Respiratory Tract Diseases (1)
Pathological Conditions, Anatomical (23) · Pathological Conditions, Signs and Symptoms (23) · Otorhinolaryngologic Diseases (22) · Polyps (22) · Respiratory Tract Diseases (22) · Nose Diseases (21) · Hemorrhage (1) · Hypersensitivity (1) · Hypersensitivity, Immediate (1) · Immune System Diseases (1) · Intraoperative Complications (1) · Lung Diseases, Obstructive (1) · Pathologic Processes (1)
Mometasone Furoate (8) · Omalizumab (3) · Fluticasone (2) · benralizumab (2) · mepolizumab (2) · Adrenal Cortex Hormones (1) · Budesonide (1) · Doxycycline (1) · Prednisolone (1) · Prednisone (1) · Standard of Care (1) · Steroids (1) · Sugars (1) · Tablets (1) · dupilumab (1)
GlaxoSmithKline (4) · Hoffmann-La Roche (3) · Intersect ENT (3) · Organon and Co (3) · AstraZeneca (2) · Optinose US Inc. (2) · Assiut University (1) · Beijing Tongren Hospital (1) · Humanitas Clinical and Research Center (1) · Novartis Pharmaceuticals (1) · Samuel Lunenfeld Research Institute, Mount Sinai Hospital (1) · Sanofi (1)
United States (14) · Poland (8) · Canada (7) · Germany (7) · Belgium (5) · Hungary (5) · Spain (5) · United Kingdom (5) · China (4) · Czechia (4) · France (4) · Italy (4) · Japan (4) · Russia (4) · Ukraine (4)
Joseph K Han, MD (2) · Aly Ragaie (1) · Brian Lipworth, MD (1) · Claus Bachert, Prof. dr. h.c. (1) · Hamza El Shafie (1) · Ian Witterick, MD FRCSC (1) · Jennifer Carothers (1) · John Messina (1) · Jose P. Stolovitzky, MD (1) · Keith D Forwith, MD (1) · Luo Zhang, MD (1) · Mai AbuElmagd (1)
PMID 33710614, PMID 33548517, PMID 37951571, PMID 38197558, PMID 34382434, PMID 37214171, PMID 40037388, PMID 41461999, PMID 19289710, PMID 23331528, PMID 26575524, PMID 26992115, PMID 30370691, PMID 31543428, PMID 33465455, PMID 33611847, PMID 34110505, PMID 34437720, PMID 34459002, PMID 34599979, PMID 34817082, PMID 34850966, PMID 34911163, PMID 34970860, PMID 35034364, PMID 35092110, PMID 35636689, PMID 35775319, PMID 35822924, PMID 36662344, PMID 37026112, PMID 37548085, PMID 37586475, PMID 38156522, PMID 39343385, PMID 39618256, PMID 40106374, PMID 42868896
2017 (4), 2015 (1), 2016 (1), 2018 (1)